Company Overview and News

1
Genetic Technologies: Catalysts For Tremendous Upside

2016-12-28 seekingalpha
The stock has near-term catalysts that may lead to significant stock price increases in the next 6-12 months. .

 
Genetic Technologies raising $8.1M for cancer risk assessment tests

2016-12-02 proactiveinvestors.com.au
The company offers predictive testing and assessment tools to proactively manage women’s health. Genetic Technologies’ lead product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer. The company is issuing 720 million fully paid ordinary shares directly to U.S. investors, represented by 4.8 million American Depositary Shares (ADS). Each ADS represents 150 ordinary shares in Genetic Technologies.

 
Genetic Technologies Announces Offering of USD 6.0 Million of American Depository Shares

2016-12-01 marketwired
MELBOURNE, AUSTRALIA--(Marketwired - Dec 1, 2016) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company"), a molecular diagnostics company and provider of BREVAGenplus®, a first-in-class, clinically validated risk assessment test for sporadic (non-hereditary) breast cancer, today announced that it has entered into a definitive agreement with U.S. institutional investors, pursuant to which the investors have agreed to purchase an aggregate of 4,800,000 American Depositary Shares ("ADSs"), each representing one hundred and fifty (150) of the Company's Ordinary Shares, at a weighted average price of $1.

2
Genetic Technologies and The University of Melbourne inks deal to develop CRC assessment test; shares up 91%

2016-11-29 seekingalpha
Genetic Technologies (GENE +91.3%) announces the signing of an exclusive worldwide license agreement with The University of Melbourne for the development and commercialization of a novel colorectal cancer (CRC) risk assessment test.

1
Genetic Technologies Practically Doubles on Licensing Agreement

2016-11-29 247wallst
Shares of Genetic Technologies Ltd. (NASDAQ: GENE) practically doubled in Tuesday’s session following a key licensing agreement. The company announced the signing of an exclusive worldwide license agreement with the University of Melbourne for the development and commercialisation of a novel colorectal cancer (CRC) risk assessment test.

 
Genetic Technologies Limited and The University of Melbourne Enter into Exclusive Worldwide License Agreement to Develop Colorectal Cancer Risk Assessment Test

2016-11-29 marketwired
MELBOURNE, AUSTRALIA--(Marketwired - Nov 29, 2016) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company"), a molecular diagnostics company and provider of BREVAGenplus®, a first-in-class, clinically validated risk assessment test for sporadic (non-hereditary) breast cancer, today announced the signing of an exclusive worldwide license agreement with The University of Melbourne for the development and commercialisation of a novel colorectal cancer (CRC) risk assessment test.

 
Genetic Technologies Launches BREVAGenplus(R) Marketing Program Around Susan G. Komen(R)'s Race for the Cure(R) Events

2016-10-03 marketwired
MELBOURNE, AUSTRALIA--(Marketwired - Oct 3, 2016) - Molecular diagnostics company Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company") announced today that it will be conducting a promotional campaign around the Susan G. Komen Race for the Cure events. This program will commence at the Susan G. Komen Dallas Race for the Cure in Dallas, on October 15 2016, which coincides with National Breast Cancer Awareness Month.

 
Genetic Tech up 50% on heavy volume; catalyst elusive

2016-09-18 seekingalpha
Thinly traded nano cap Genetic Technologies (GENE +50.2%) zooms up on a massive 35x surge in volume. Surprisingly, no particular news accounts for the action.

 
Genetic Tech requests trading halt

2016-09-18 seekingalpha
Australia-based Genetic Technologies (OTC:GNTLF) requests a suspension of trading in its shares on the Australian Exchange (ASX:GTG) pending its announcement concerning the finalization of a proposed financing. It requests the suspension to remain in place until the announcement is made or normal exchange trading resumes on Monday, September 15, 2014.

 
Rapid Litigation Management Ltd., Formerly Celsis Holdings, Inc., in Vitro, Inc., Plaintiffs-Appellants v. Cellzdirect, Inc., a Delaware Corporation and Wholly-owned Subsidiary, Invitrogen Corporation, a Delaware Corporation, Defendants-Appellees

2016-07-07 caselaw.findlaw
Rapid Litigation Management Ltd., Formerly Celsis Holdings, Inc., in Vitro, Inc., Plaintiffs-Appellants v. Cellzdirect, Inc., a Delaware Corporation and Wholly-owned Subsidiary, Invitrogen Corporation, a Delaware Corporation, Defendants-Appellees

 
Genetic Technologies Limited Announces Appointment Of Senior Medical Director

2016-06-22 devicespace
MELBOURNE, AUSTRALIA--(Marketwired - June 21, 2016) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company"), a molecular diagnostics company specializing in women's health, and provider of BREVAGenplus®, a first-in-class, clinically validated risk assessment test for sporadic breast cancer, is pleased to announce the appointment of Dr. Susan J. Gross, MD, FRCSC, FACOG, FACMG as Senior Medical Director, effective 20 June 2016.

 
Genetic Technologies and Verizon IndyCar Series Driver Pippa Mann Update BREVAGenplus(R) Marketing Partnership

2016-06-22 marketwired
MELBOURNE, AUSTRALIA--(Marketwired - Jun 22, 2016) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company"), a molecular diagnostics company specializing in women's health, and provider of BREVAGenplus®, a first-in-class, clinically validated risk assessment test for sporadic breast cancer, announced today an update on its marketing partnership with Verizon IndyCar Series driver, Pippa Mann.

 
Genetic Technologies Announces Appointment of Senior Medical Director

2016-06-21 marketwired
MELBOURNE, AUSTRALIA--(Marketwired - Jun 21, 2016) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company"), a molecular diagnostics company specializing in women's health, and provider of BREVAGenplus®, a first-in-class, clinically validated risk assessment test for sporadic breast cancer, is pleased to announce the appointment of Dr. Susan J. Gross, MD, FRCSC, FACOG, FACMG as Senior Medical Director, effective 20 June 2016.

 
Genetic Technologies Limited To Ring The Nasdaq Stock Market Closing Bell

2016-05-05 devicespace
What: Genetic Technologies Limited (Nasdaq:GENE), a molecular diagnostics company specializing in women’s health, and provider of BREVAGenplus®, a first-in-class, clinically validated risk assessment test for sporadic breast cancer, will visit the Nasdaq MarketSite in Times Square.

 
Genetic Technologies and Verizon IndyCar Series Driver Pippa Mann to Ring Nasdaq Stock Market Closing Bell on May 6th, 2016

2016-05-04 marketwired
MELBOURNE, AUSTRALIA--(Marketwired - May 4, 2016) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company"), a molecular diagnostics company specializing in women's health, and provider of BREVAGenplus®, a first-in-class, clinically validated risk assessment test for sporadic breast cancer, announced today that it will visit the Nasdaq MarketSite in New York City's Times Square and ring the Closing Bell on Friday, May 6th, 2016.

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...